Perseus Proteomics Inc. Logo

Perseus Proteomics Inc.

Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.

4882 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
目黒区駒場四丁目7番6号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perseus Proteomics Inc. is a drug discovery biotechnology company founded in 2001 as a venture from the University of Tokyo. The company focuses on creating novel antibody-based therapeutics to treat cancer and other diseases, utilizing its proprietary and unique antibody technologies. Its business operations are structured around three core segments: Drug Discovery, which develops its pipeline of potential antibody drugs; Antibody Research Support Services for partner institutions; and the direct sale of antibody products and diagnostic reagents, such as ELISA kits. The company's mission is to contribute to global healthcare by developing innovative treatments for people suffering from diseases worldwide.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Perseus Proteomics Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 09:28
Regulatory News Service
臨時報告書
Japanese 25.9 KB
2025-06-27 08:34
Regulatory News Service
確認書
Japanese 8.2 KB
2025-06-27 08:33
Regulatory News Service
訂正有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2025-06-27 08:33
Regulatory News Service
確認書
Japanese 8.2 KB
2025-06-27 08:32
Regulatory News Service
訂正有価証券報告書-第23期(2022/04/01-2023/03/31)
Japanese 1.5 MB
2025-06-27 08:32
Regulatory News Service
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.4 KB
2025-06-27 08:31
Regulatory News Service
確認書
Japanese 8.1 KB
2025-06-27 08:31
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 2.6 MB
2025-05-21 08:31
Regulatory News Service
臨時報告書
Japanese 20.2 KB
2024-11-14 07:34
Regulatory News Service
確認書
Japanese 8.1 KB
2024-11-14 07:34
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 163.4 KB
2024-06-20 07:40
Regulatory News Service
臨時報告書
Japanese 23.6 KB
2024-06-20 07:34
Regulatory News Service
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-20 07:34
Regulatory News Service
確認書
Japanese 8.1 KB
2024-06-20 07:33
Annual Report
有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 2.8 MB

Automate Your Workflow. Get a real-time feed of all Perseus Proteomics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Perseus Proteomics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.